FDA Clearance Tracker · K964406
AUTOMATED MULTI-POINT BLOOD VOLUME ANALYZER
Last checked: Nov 20, 2026Latest source record: Sep 25, 1997 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 1997
Substantially Equivalent
Time to decision
325 days
Received Nov 4, 1996. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K964406
- Device name
- AUTOMATED MULTI-POINT BLOOD VOLUME ANALYZER
- Applicant
- Daxor Corporation
- Applicant location
- New York, NY
- Received
- Nov 4, 1996
- Decided
- Sep 25, 1997
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Device, Blood Volume Measuring (JWO)
- Device class
- Class II
- Regulation
- 21 CFR 864.5950
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code JWO (Device, Blood Volume Measuring).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K964406
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Daxor Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261099 · Decided Jun 18, 2026 · 77 days after receipt
Device type: Device, Blood Volume Measuring (JWO) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.